Abeona Therapeutics Inc
Veridion Score
Composite trend over time
Why is ABEO moving today?
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ABEO.
ABEO insider activity
Abeona Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$3.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | 2026-06-15 | Silverstein Christine Berni | Insider | sell | $5.71 | 18,160 | 119,562 | $104K | SEC Form 4 |
| 2026-06-09 | 2026-06-09 | Vasanthavada Madhav | Insider | sell | $5.30 | 5,450 | 303,451 | $29K | SEC Form 4 |
| 2026-06-09 | 2026-06-09 | O'Malley Brendan M. | Insider | sell | $5.30 | 6,305 | 440,003 | $33K | SEC Form 4 |
| 2026-06-09 | 2026-06-09 | Seshadri Vishwas | Insider | sell | $5.30 | 31,916 | 1,374,079 | $169K | SEC Form 4 |
| 2026-06-09 | 2026-06-09 | Vazzano Joseph Walter | Insider | sell | $5.39 | 25,646 | 518,437 | $138K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 38 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moABEO contract awards, year to date.
Public federal awards linked to this ticker.
ABEO lobbying filings, year to date.
Registered lobbying filings matched to Abeona Therapeutics Inc.